Florence L.
- Country
- France
- Department
- hématologie
Research Overview
- Phase 3 Study of Isatuximab, Lenalidomide, and Dexamethasone ± Bortezomib in Non-Frail, Transplant-Ineligible Elderly Patients with Newly Diagnosed Multiple Myeloma
- Phase 3 Evaluation of Lenalidomide and Daratumumab SC Versus Lenalidomide and Dexamethasone in Frail, Newly Diagnosed Multiple Myeloma Patients Ineligible for High-Dose Therapy
Data & Insights
Has run more than one trial at 42 of 87 partner sites.
Specializations
Hematologic Oncology
The investigator specializes in treating multiple myeloma, with particular emphasis on therapeutic approaches for elderly and transplant-ineligible patients.
- Newly diagnosed multiple myeloma management
- Elderly patient care optimization
- Non-transplant therapeutic strategies
Focus includes evaluating novel treatment combinations for patients aged 65-80 years who are not eligible for transplantation.
Targeted Therapies
Expertise in implementing innovative therapeutic combinations incorporating monoclonal antibodies and immunomodulatory drugs.
- Isatuximab-based regimens
- Daratumumab subcutaneous administration
- Lenalidomide combinations
Special interest in developing treatment protocols that balance efficacy with tolerability for frail patients.
Treatment Response Assessment
Specialized in evaluating treatment effectiveness through advanced response monitoring techniques.
- Minimal Residual Disease assessment
- Progression-free survival evaluation
- Long-term response monitoring
Employs sophisticated methods to measure treatment outcomes in elderly myeloma patients.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.